Terms: = Kidney tumors AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1
45 results:
1. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
[TBL] [Abstract] [Full Text] [Related]
2. The risk of acute kidney injury in colorectal cancer survivors: an english population-based matched cohort study.
Andresen K; Carreira H; Strongman H; McDonald HI; Benitez-Majano S; Mansfield KE; Nitsch D; Tomlinson LA; Bhaskaran K
BMC Cancer; 2023 Sep; 23(1):839. PubMed ID: 37679679
[TBL] [Abstract] [Full Text] [Related]
3. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract] [Full Text] [Related]
4. Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report.
Wei W; Liu J; Wang L; Duan X; Ding D
BMC Urol; 2023 Jun; 23(1):103. PubMed ID: 37277741
[TBL] [Abstract] [Full Text] [Related]
5. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
[TBL] [Abstract] [Full Text] [Related]
6. A novel autophagy-related long non-coding RNAs prognostic risk score for clear cell renal cell carcinoma.
Tang F; Tang Z; Lu Z; Cai Y; Lai Y; Mai Y; Li Z; Lu Z; Zhang J; Li Z; He Z
BMC Urol; 2022 Dec; 22(1):203. PubMed ID: 36496360
[TBL] [Abstract] [Full Text] [Related]
7. Seasonal variations in the diagnosis of the top 10 cancers in Korea: A nationwide population-based study using a common data model.
Yoon JY; Kwak MS; Kim HI; Cha JM
J Gastroenterol Hepatol; 2021 Dec; 36(12):3371-3380. PubMed ID: 34293206
[TBL] [Abstract] [Full Text] [Related]
8. ZNF668: a new diagnostic predictor of kidney renal clear cell carcinoma.
Wei C; Gao Y; Chen X; Zhao C; Li P
Anticancer Drugs; 2022 Jan; 33(1):e491-e499. PubMed ID: 34261923
[TBL] [Abstract] [Full Text] [Related]
9. Reasons for intending to accept or decline kidney cancer screening: thematic analysis of free text from an online survey.
Freer-Smith C; Harvey-Kelly L; Mills K; Harrison H; Rossi SH; Griffin SJ; Stewart GD; Usher-Smith JA
BMJ Open; 2021 May; 11(5):e044961. PubMed ID: 34006549
[TBL] [Abstract] [Full Text] [Related]
10. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract] [Full Text] [Related]
11. Nephrometry scores: a validation of three systems for peri-operative outcomes in retroperitoneal robot-assisted partial nephrectomy.
Crockett MG; Giona S; Whiting D; Whitehurst L; Agag A; Malki M; Hussain M; Barber NJ
BJU Int; 2021 Jul; 128(1):36-45. PubMed ID: 33001563
[TBL] [Abstract] [Full Text] [Related]
12. Perioperative Risk Factors Associated With Acute kidney Injury in Patients After Brain Tumor Resection.
Li J; Zhao Y; Yan X; Li R; Zhang X; Zeng M; Dong J; Li S; Peng Y; Han R
J Neurosurg Anesthesiol; 2022 Jan; 34(1):51-56. PubMed ID: 32658102
[TBL] [Abstract] [Full Text] [Related]
13. Improving survival prediction using a novel feature selection and feature reduction framework based on the integration of clinical and molecular data.
Neums L; Meier R; Koestler DC; Thompson JA
Pac Symp Biocomput; 2020; 25():415-426. PubMed ID: 31797615
[TBL] [Abstract] [Full Text] [Related]
14. Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Kim KH; Lee HH; Yoon YE; Na JC; Kim KS; Han WK
Investig Clin Urol; 2019 Nov; 60(6):425-431. PubMed ID: 31692952
[TBL] [Abstract] [Full Text] [Related]
15. Intraindividual Comparison of
Dietlein F; Kobe C; Hohberg M; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Persigehl T; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 May; 61(5):729-734. PubMed ID: 31628219
[No Abstract] [Full Text] [Related]
16. Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function.
McIntosh AG; Parker DC; Egleston BL; Uzzo RG; Haseebuddin M; Joshi SS; Viterbo R; Greenberg RE; Chen DYT; Smaldone MC; Kutikov A
BJU Int; 2019 Dec; 124(6):999-1005. PubMed ID: 31145523
[TBL] [Abstract] [Full Text] [Related]
17. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract] [Full Text] [Related]
18. Cancer risk by the subtype of alopecia.
Lee JH; Song Y; Do Han K; Park YM; Lee JY; Park YG; Lee YB
Sci Rep; 2018 Jun; 8(1):9748. PubMed ID: 29950587
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative Global Proteome and Lysine Succinylome Analyses Reveal the Effects of Energy Metabolism in Renal Cell Carcinoma.
Zhang N; Gao R; Yang J; Zhu Y; Zhang Z; Xu X; Wang J; Liu X; Li Z; Li Z; Gong D; Li J; Bi J; Kong C
Proteomics; 2018 Oct; 18(19):e1800001. PubMed ID: 29882248
[TBL] [Abstract] [Full Text] [Related]
20. [Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75].
Cholley I; Correas JM; Masson-Lecomte A; Sanchez S; Champy C; Le Guilchet T; Ariane M; Hurel S; Audenet F; Thiounn N; Fontaine E; Mejean A; Timsit MO
Prog Urol; 2018 Jan; 28(1):55-61. PubMed ID: 29174691
[TBL] [Abstract] [Full Text] [Related]
[Next]
